CRKL and hepatocellular carcinoma: In HCC, upregulation of the CRKL/β‐catenin/VEGFα axis mediates PD‐1 inhibitor resistance by enhancing TANs infiltration, supporting the strategy of combining CRKL inhibitors with anti‐PD‐1 agents.159